BCMA-directed CAR-T cell therapy induces durable drug-free remission in refractory primary immune thrombocytopenia
Abstract
This first clinical evaluation of BCMA CAR-T cell therapy in four patients with refractory primary ITP demonstrated manageable safety, rapid and sustained platelet recovery, and durable drug-free complete remission lasting up to 15 months, supporting further evaluation in larger studies.
Article Details
Authors (9)
Jinhui Shu
Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
Min Xu
Peiru Li
Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
Wei Xie
Lin Liu
Hongjian Li
James B. Bussel
Department of Pediatrics, Division of Hematology/Oncology, Weill Cornell Medicine, New York, New York, United States
Yu Hu
Heng Mei
Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Hubei Provincial Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, China